Pharmacy Billing Services · 340B · 2026

340B Modifiers and Specialty Drugs, Decoded for 2026

JG and TB look like a two-character afterthought on a claim line. They are actually the tripwire that decides whether a 340B specialty-drug claim pays clean, sits in an edit, or comes back as an overpayment demand.

The short answer: Under the CMS CY2026 OPPS/ASC final rule, 340B-acquired drugs are still paid at ASP + 6%, the same rate as non-340B drugs. The differential payment era is over, but the modifier is not optional. Non-exempt hospitals append JG, rural sole-community, critical-access, children's, and PPS-exempt cancer hospitals append TB for informational tracking. Get the modifier, the benefit lane, and the state Medicaid rule right, or the money leaks on the back end.
JG non-exempt hospital 340B TB exempt-entity informational Rate ASP + 6% (CY2026) Pharmacy NCPDP D.0 Medical 837 / J-code buy-and-bill

The two modifiers, side by side

JG and TB are not interchangeable

The wrong one is not a payment problem on day one. It is an audit finding later, because the modifier tells CMS which covered-entity class the site is and whether the drug was 340B-acquired at all.

JG

Non-exempt hospitals

Disproportionate-share hospitals and other non-exempt covered entities append JG to 340B-acquired separately payable drugs and biologicals billed under the medical benefit.

Applies toDSH, non-exempt CEs
CY2026 paymentASP + 6%
Purpose340B identification
Claim laneOPPS / 837I
TB

Exempt entities, informational

Rural sole community hospitals, critical access hospitals, children's hospitals, and PPS-exempt cancer hospitals report TB for informational purposes only. Payment is unchanged.

Applies toRSCH, CAH, children's, cancer
CY2026 paymentASP + 6%
PurposeInformational tracking
Claim laneOPPS / 837I

The medical-benefit question

One drug, two possible lanes

A specialty drug can adjudicate under the medical benefit (buy-and-bill, J-code, ASP pricing, 837 claim) or the pharmacy benefit (point of sale, NCPDP D.0, NDC pricing). The lane decides the modifier set, the price basis, and who holds the 340B duplicate-discount risk. Reading this wrong is the most expensive quiet mistake in specialty billing.

Specialty drug ordered Medical benefit buy-and-bill · J-code · ASP Pharmacy benefit point of sale · NDC · NCPDP D.0 JG / TB modifier on the medical claim line Submission Clarification code 20 (340B) in NCPDP Duplicate-discount risk lives here
Medical: JG/TB rides the 837, priced off ASP. Pharmacy: NCPDP D.0 Submission Clarification Code 20 flags 340B. Watch: a drug flipped from medical to pharmacy carries a different 340B flag entirely.

The full modifier set on a 340B drug line

JG and TB never travel alone

On a real specialty-drug claim, the 340B modifier sits next to wastage and Medicaid modifiers. Miss one and the line either underpays, overpays, or trips a duplicate-discount edit.

ModifierMeaningWhere it lives2026 status
JGDrug acquired under 340B, non-exempt hospitalMedical / OPPS lineRequired
TBDrug acquired under 340B, exempt entity, informationalMedical / OPPS lineInformational
JWDrug amount discarded / not administeredSeparate wastage lineRequired
JZZero drug amount discardedSame admin lineRequired
UDMedicaid 340B acquisition identifier (many states)Medicaid claim lineState-specific
SCC 20NCPDP Submission Clarification Code, 340B at point of salePharmacy / NCPDP D.0Pharmacy lane

The 2026 geo-grid

340B rules do not stop at the modifier. They change at the state line.

Medicare pays 340B drugs the same everywhere in 2026. State Medicaid programs do not. The duplicate-discount prohibition means each state decides how covered entities identify 340B claims, whether they carve in or carve out of managed care, and what price basis applies. This grid maps the pattern operators actually hit.

Carve-out tendency (bill FFS, exclude from MCO) Carve-in tendency (bill through managed care)
CA
California · Medi-Cal Rx
CARVE-OUT
  • ID 340B claim flag + actual acquisition cost
  • Pharmacy carved to single Medi-Cal Rx PBM
NY
New York · Medicaid
CARVE-OUT
  • ID 340B identifier required to block rebate
  • Pharmacy Medicaid Rx carved out of MCOs
TX
Texas · Medicaid
CARVE-IN
  • ID UD-type 340B flag on claim
  • Medical verify MCO-specific 340B policy
FL
Florida · Medicaid
CARVE-IN
  • ID 340B modifier per provider manual
  • Plans managed-care plan rules vary by drug
OH
Ohio · Medicaid
CARVE-OUT
  • ID single-PBM 340B claim identification
  • Pharmacy unified pharmacy program
WA
Washington · Apple Health
CARVE-OUT
  • ID 340B acquisition cost basis
  • Rule covered-entity attestation on file
GA
Georgia · Medicaid
CARVE-IN
  • ID 340B flag on medical + pharmacy
  • Plans CMO-level policy check needed
IL
Illinois · Medicaid
CARVE-IN
  • ID UD-type identifier per manual
  • Medical J-code buy-and-bill flagged
Read this as a pattern map, not a rulebook. Carve-in / carve-out status, the exact 340B claim identifier, and price basis change with each state's current Medicaid pharmacy and provider manuals and managed-care contracts. Before you bill, confirm the live rule in that state's Medicaid manual and the specific MCO or PBM policy. The duplicate-discount prohibition under the Medicaid Drug Rebate Program is the constant. Everything above it moves.

Cite the source, not the rumor

The 2026 guidelines this all rests on

Every position above traces to a named federal source. Keep these where your billing team can reach them.

CMS

CY2026 OPPS/ASC Final Rule

Sets 340B-acquired drug payment at ASP + 6% and retains JG and TB modifier reporting for covered-entity hospitals under the Outpatient Prospective Payment System.

CMS

CY2026 Physician Fee Schedule

Governs Part B drug payment methodology and the ASP-based pricing that anchors medical-benefit buy-and-bill for specialty drugs.

CMS · Section 1847A

Average Sales Price (ASP) Methodology

The statutory basis for ASP + 6% Part B drug pricing, updated on the quarterly ASP pricing files that drive every J-code reimbursement.

HRSA · PHSA §340B

340B Drug Pricing Program

Section 340B of the Public Health Service Act defines covered entities and the ceiling price, and forbids duplicate discounts with Medicaid rebates.

NCPDP

Telecommunication Standard D.0

The pharmacy-benefit claim standard. Submission Clarification Code 20 flags a 340B-acquired drug at point of sale, the pharmacy-lane counterpart to JG/TB.

CMS · MDRP

Medicaid Drug Rebate Program

The duplicate-discount prohibition that forces state-by-state 340B claim identification, carve-in versus carve-out, and the UD modifier patterns in the grid above.

Where the money quietly leaks

Four failure points on a single 340B specialty line

JG↔TB
Wrong modifier for the entity class becomes an audit finding, not a day-one denial.
Lane
Drug flipped medical to pharmacy carries a different 340B flag and price basis.
JW/JZ
Missing wastage modifier on a high-cost vial invites recoupment on the discarded amount.
Dup.
No state 340B identifier triggers a duplicate-discount edit and a rebate clawback.

Your specialty-drug lines should never guess

ASP-RCM Solutions builds pharmacy billing services around exactly this: the modifier logic, the medical-versus-pharmacy lane decision, and a live state Medicaid 340B matrix your billers actually work from. We turn the geo-grid above into rules inside your workflow so JG, TB, JW, JZ, and the duplicate-discount flags land right the first time.

  • 340B modifier and lane audit on your real claims
  • State-by-state Medicaid 340B rule mapping
  • Duplicate-discount and wastage edit prevention
Talk to our pharmacy billing team →

This page is educational guidance for revenue-cycle operators and does not replace the current CMS, HRSA, NCPDP, or individual state Medicaid manuals. Confirm every 340B modifier, benefit-lane, and duplicate-discount rule against the live source before billing.